Xintela takes up convertible loan of SEK 30 million
The loan from main owner Flerie Invest will accelerate XSTEM development and repay previous loan.
See the latest news and media coverage for Xintela. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharma company developing stem cell and cancer therapies
xintela.seLast updated
In short: Xintela advanced its XSTEM stem cell platform through positive clinical trials, secured major funding from Flerie Invest, and won key patents.
The loan from main owner Flerie Invest will accelerate XSTEM development and repay previous loan.
No serious adverse events were reported, and the company plans to evaluate XSTEM on other wound indications.
Net sales increased to 443 KSEK and profit before tax was -11,780 KSEK. Several advances with XSTEM and patents.
The board was re-elected with new appointments, share issue authorizations were approved, no dividend.
Xintela (XINT) announces today that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of the company's stem cell...
Find the latest Xintela AB (publ) (XINT.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.
Visit a quote page and your recently viewed tickers will be displayed here.
Xintela (XINT) announces that the last patient has been dosed in the company's clinical Phase I/IIa study with XSTEM® in patients with difficult-to-heal venous leg...
Track Xintela and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Xintela and other trending companies.